Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum

Shahariar Mohammed Fahim; Jeffrey A Tice; Linda Luu; Josh J Carlson; Marina Richardson; Belen Herce-Hagiwara; Ronald Dickerson; Daniel A Ollendorf

doi:10.18553/jmcp.2024.30.12.1479

Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum

J Manag Care Spec Pharm. 2024 Dec;30(12):1479-1485. doi: 10.18553/jmcp.2024.30.12.1479.

Authors

Shahariar Mohammed Fahim¹, Jeffrey A Tice², Linda Luu³, Josh J Carlson³, Marina Richardson¹, Belen Herce-Hagiwara¹, Ronald Dickerson³, Daniel A Ollendorf¹

Affiliations

¹ Institute for Clinical and Economic Review, Boston, MA.
² Division of General Internal Medicine, University of California San Francisco.
³ Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle.

No abstract available

Grants and funding

Through their affiliated institutions, Drs Tice and Carlson, Ms Luu, and Mr Dickerson received funding from ICER for the work described in this summary.